Orthocell has today announced that it has completed a Company-led Strategic Placement to raise $3.5 million.
The Company welcomes prominent investors Mr Chris Ellison, Mr Rod Jones, Mr Michael Malone, the McCusker Family and the Merchant Biotech Fund, which significantly strengthens the Company’s share register.
With the strategic placement now complete, the Company is well funded to execute its global market expansion strategy and the pivotal US product registration for Remplir™, expected in Q1 CY24.
Orthocell Chair, John Van Der Wielen, said:
“The support of these strategic investors is an endorsement of Orthocell’s science, business strategy and progress in commercialising its leading bone and nerve repair products, and the exciting outlook for the Company as it progresses approvals in new key jurisdictions like the US. The Board and I would like to welcome the new investors to the register.”